RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., a global leader in metabolomics, announced today that it has partnered with Metdia Biotech, S.L. to commercialize its Quantose IR™ and Quantose IGT™ prediabetes tests in Europe. These laboratory-developed tests (LDTs) can be used in the risk assessment, monitoring and, with appropriate intervention, prevention of prediabetes and type 2 diabetes. Metdia will market the tests to hospitals and clinical laboratories in Spain, Portugal, France, Italy, the United Kingdom, Germany, Switzerland, Sweden, Norway, Denmark, Finland, the Netherlands, Belgium and Austria.
“Diabetes is a significant global health concern, and the costs to society are high and growing rapidly,” said Oscar Rodríguez, director of Metdia Biotech. “According to the International Diabetes Federation, more than 55 million adults in the European Region are coping with diabetes every day. Another 66 million have impaired glucose tolerance, a known risk factor for prediabetes. Tests using Metabolon’s Quantose technology provide cost-effective assessment tools that help physicians identify patients with prediabetes and monitor the impact of therapeutic interventions. If prediabetes is caught early, physicians can prescribe treatment that might prevent progression to type 2 diabetes.”
“Licensing our Quantose IR and Quantose IGT technology to Metdia in Europe is an important next step in expanding the availability of these obesity-related diagnostic tests outside the U.S.,” stated John Ryals, Ph.D., president and CEO at Metabolon. “We are confident in Metdia’s broad knowledge of the Molecular Diagnostics Market in Europe. Earlier this year, Quantose IR became commercially available in Mexico through Patia Biopharma, a leading Latin American diabetes public health company. We are delighted to see our technology available to contribute to the health of millions of people in these two major markets.”
Most people with prediabetes do not know they have it. A person with prediabetes has a blood sugar level higher than normal, but not high enough for a diagnosis of type 2 diabetes. If left untreated, individuals with prediabetes are at high risk of progressing to type 2 diabetes, for which there is no cure. Research has shown that many of the complications associated with diabetes are already developing during the prediabetes phase. Diabetes is a leading cause of heart disease, stroke, kidney disease, blindness and amputation.
About Quantose IR
Quantose IR is an LDT that
reflects insulin resistance. This blood test is based on insulin and
three non-glycemic biomarkers. It assesses risk of progression to
prediabetes earlier than traditional glycemic measures such a hemoglobin
A1c. By reflecting insulin resistance, Quantose IR provides
clinicians with useful information that goes beyond glycemic measures to
stratify their patients by level of insulin sensitivity.
About Quantose IGT
Quantose IGT is an LDT that
reflects the degree of impaired glucose tolerance. Impaired glucose
tolerance is a core metabolic defect in dysglycemia and is a known risk
factor for prediabetes. Quantose IGT may be used as an
alternative to an oral glucose tolerance test (OGTT) or to identify
patients who may be candidates for an OGTT.
About Metdia Biotech
Metdia Biotech, S.L. is a Spanish
biomedical company focused on providing European citizens with
disruptive technologies and devices to prevent, diagnose and monitor the
treatment of prediabetes and diabetes.
About Metabolon
Founded in 2000 and headquartered in
Research Triangle Park, North Carolina, Metabolon, Inc. is the world’s
most advanced life sciences company focused on metabolomics. Its
proprietary technology and informatics provide insight into systems
biology and advance research and product development across the
pharmaceutical, biotechnology, consumer products, agricultural, pet care
and nutrition industries, as well as government and academic
institutions. The company has conducted more than 3,000 metabolic
phenotyping studies for more than 600 clients. Metabolon’s in-depth
understanding of biochemical pathways and effects has led it to unique
biomarker discoveries, the development of innovative diagnostic tests
and breakthroughs in personalized medicine. For more information, please
visit www.metabolon.com.
Cautionary Note about Forward-Looking Statements
The
materials provided herein that are not historical facts are or might
constitute projections and other forward-looking statements regarding
future events that involve substantial risks, uncertainties and
assumptions. If any of these risks or uncertainties materialize, or if
any of these assumptions prove to be incorrect, Metabolon’s results
could differ materially from the results expressed or implied by any
forward-looking statements. The risks, uncertainties and assumptions
referred to above include, but are not limited to: the uncertainties
inherent in biochemical research and development; decisions by
regulatory authorities regarding whether and when to approve diagnostic
tests; Metabolon’s and its distributors’ ability to successfully
commercialize and market both new and existing products; governmental
laws and regulations affecting health care, including access, pricing
and reimbursement of diagnostic tests; the strength of Metabolon’s
intellectual property portfolio; Metabolon’s history of operating
losses; whether Metabolon is able to achieve or sustain profitability;
its highly competitive industry; its ability to compete effectively;
security and privacy risks; and Metabolon’s ability to continue to
innovate and provide products and services that are useful to its
clients, among other risks, uncertainties and assumptions.